Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Biomerieux (BIM) EUR1

Sell:€108.00 Buy:€109.50 Change: €2.30 (2.11%)
Market closed |  Prices as at close on 4 March 2021 | Switch to live prices |
Change: €2.30 (2.11%)
Market closed |  Prices as at close on 4 March 2021 | Switch to live prices |
Change: €2.30 (2.11%)
Market closed |  Prices as at close on 4 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Contact details

376 chemin de l'Orme
+33 (4) 78872000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€12.65 billion
Shares in issue:
118.32 million
Health Care Equipment
Euronext Paris

Key personnel

  • Alexandre Merieux
    Chairman of the Board, Chairman of the Executive Committee, Chief Executive Officer, Non-Independent Director
  • Guillaume Bouhours
    Executive Vice President Purchasing and Information Systems, Chief Financial Officer, Member of the Executive Board
  • Pierre Boulud
    Chief Operating Officer, Clinical Operations
  • Valerie Leylde
    Executive Vice President of Human Resources and Communications, Member of the Executive Committee
  • Francois Lacoste
    Executive Vice President, R&D, Member of the Executive Board
  • Mark Miller
    Executive Vice President, Chief Medical Officer, Member of the Executive Board
  • Yasha Mitrotti
    Executive Vice President - Industrial Microbiology, Member of the Executive Board
  • Esther Wick
    Executive Vice President - Legal Affairs, Intellectual Property and Compliance, Member of the Executive Board
  • Nicolas Cartier
    Executive Vice President - Industry Unit
  • Randy Rasmussen
    Executive Vice President - Molecular biology

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.